Novo Nordisk's Awiqli®, The First Once-Weekly Basal Insulin For Adults With Type 2 Diabetes, Now Available In The US
NVO•Awiqli now available in the US
Aug. 11 (Reuters) - Novo Nordisk A/S:
- Novo Nordisk's Awiqli®, the first once-weekly basal insulin for adults with type 2 diabetes, now available in the US
- Novo Nordisk - eligible patients can pay as little as $35 per month for Awiqli
